Drug intelligence / Profile preview

palmitoylethanolamide + resveratrol

Development stage
Unknown
Lead developer
Gencor
Modality
Small Molecules
Administration
Oral
01

Overview

Levagen + resveratrol is an oral nutraceutical combination developed by RDC Global Pty Ltd, specifically designed to address pain and inflammation associated with menstrual disorders. The product combines Levagen+, a highly bioavailable formulation of palmitoylethanolamide (PEA) utilizing LipiSperse® dispersion technology, with the polyphenolic antioxidant resveratrol. PEA is an endogenous fatty acid amide that exerts analgesic and anti-inflammatory effects by modulating endocannabinoid-like receptors and prostaglandin-mediated pathways. The LipiSperse® technology enhances the bioavailability of PEA by approximately 1.75 times compared to standard formulations. This combination is currently being evaluated in a Phase 3/4 clinical trial for the treatment of primary dysmenorrhea in adult women.

Brand names
Levagen + resveratrol
Other names
PEA + resveratrol
02

Targets

GPR55 (G protein-coupled receptor 55)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on palmitoylethanolamide + resveratrol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on palmitoylethanolamide + resveratrol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call